10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2013

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to ______

Commission file number 0-27119

SCIVANTA MEDICAL CORPORATION

 (Exact name of registrant as specified in its charter)

Nevada	22-2436721
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

215 Morris Avenue, Spring Lake, New Jersey 07762

(Address of principal executive offices)

(732) 282-1620

(Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.         Yes xNo¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   x     No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer,” and smaller reporting company in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes¨No x

As of September 13, 2013, there were 5,429,384 shares of the registrant’s common stock, par value $.001 per share, outstanding.

SCIVANTA MEDICAL CORPORATION

INDEX TO FORM 10-Q

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Balance Sheets (unaudited) as of July 31, 2013 and October 31, 2012	2
	Statements of Operations (unaudited) for the three and nine months ended July 31, 2013 and 2012	3
	Statements of Cash Flows (unaudited) for the nine months ended July 31, 2013 and 2012	4
	Notes to the Unaudited Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17
Item 4.	Controls and Procedures	17
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	Exhibits	18
Signatures		19
Index of Exhibits		E-1

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information included in this quarterly report on Form 10-Q and other filings of the registrant under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as well as information communicated orally or in writing between the dates of such filings, contains or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act.  All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may”, “could”, “estimate”, “intend”, “continue”, “believe”, “expect” or “anticipate” or other similar words.  These forward-looking statements present our estimates and assumptions only as of the date of this quarterly report on Form 10-Q.  Except as may be required under applicable securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.  You should, however, consult further disclosures we make in future filings of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.  Additionally, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 most likely do not apply to our forward-looking statements because we are considered a penny stock issuer.

PART I.  FINANCIAL INFORMATION

Item 1.               Financial Statements

The balance sheet as of July 31, 2013, the related statements of operations for the three and nine months ended July 31, 2013 and 2012 and cash flows for the nine months ended July 31, 2013 and 2012 for Scivanta Medical Corporation (“Scivanta” or the “Company”) included in Item 1, have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).  Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted from the following financial statements pursuant to the rules and regulations of the SEC.   In the opinion of management, the accompanying financial statements include all adjustments, which are of a normal and recurring nature, necessary to present fairly our financial position and results of operations.  It is suggested that the following financial statements be read in conjunction with the financial statements and notes thereto included in the registrant’s annual report on Form 10-K for the fiscal year ended October 31, 2012.

The results of operations for the three and nine months ended July 31, 2013 and 2012, respectively, are not necessarily indicative of the results of the entire fiscal year or for any other period.

1

Scivanta Medical Corporation

Balance Sheets

(Unaudited)

	July 31, 2013			October 31, 2012
Assets
Current assets:
Cash	$	36,073		$	64,325
Prepaid expenses		16,254			9,543
Total current assets	$	52,327		$	73,868
Liabilities and Stockholders’ Deficiency
Current liabilities:
Accounts payable	$	277,126		$	222,845
Accounts payable - related party		57,389			82,651
Accrued expenses		30,321			90,043
Accrued compensation		--			225,627
Notes payable		11,407			105,000
Convertible debentures		300,000			25,000
Total current liabilities		676,243			751,166
Convertible debenture		100,000			375,000
Note payable		105,000			--
Total liabilities		881,243			1,126,166
Commitments
Stockholders' deficiency:
Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued		--			--
Common stock, $.001 par value; 500,000,000 and 10,000,000 shares authorized, respectively; 5,429,384 and 3,111,691 shares issued and outstanding, respectively		5,429			3,112
Additional paid-in capital		22,880,390			22,371,230
Accumulated deficit		(23,714,735	)		(23,426,640	)
Total stockholders' deficiency		(828,916	)		(1,052,298	)
Total liabilities and stockholders' deficiency	$	52,327		$	73,868

The accompanying notes are an integral part of these financial statements.

2

Scivanta Medical Corporation

Statements of Operations

(Unaudited)

	Three Months Ended July 31,						Nine Months Ended July 31,
	2013			2012			2013			2012
Revenue	$	--		$	--		$	--		$	--
Operating expenses:
Research and development		3,115			5,540			3,115			14,430
General and administrative		65,389			62,209			260,551			180,562
Loss from operations		(68,504	)		(67,749	)		(263,666	)		(194,992	)
Interest expense		(8,296	)		(6,217	)		(24,429	)		(19,349	)
Loss on conversion of convertible debentures		--			--			--			(21,750	)
Net loss	$	(76,800	)	$	(73,966	)	$	(288,095	)	$	(236,091	)
Net loss per common share, basic and diluted	$	(0.01	)	$	(0.02	)	$	(0.06	)	$	(0.08	)
Weighted average number of common shares outstanding, basic and diluted		5,429,384			3,111,691			4,494,496			3,098,337

The accompanying notes are an integral part of these financial statements.

3

Scivanta Medical Corporation

Statements of Cash Flows

(Unaudited)

	Nine Months Ended July 31,
	2013			2012
Cash flows from operating activities:
Net loss	$	(288,095	)	$	(236,091	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense		4,725			3,716
Loss on conversion of convertible debentures		--			21,750
Changes in operating assets and liabilities:
Grant receivable		--			131,979
Prepaid expenses		13,509			12,633
Accounts payable		71,281			18,881
Accounts payable - related party		69,738			25,566
Accrued expenses		(10,597	)		3,770
Net cash used in operating activities		(139,439	)		(17,796	)
Cash flows from financing activities:
Repayment of notes payable		(8,813	)		(10,455	)
Proceeds from sale of common stock, net of offering costs		120,000			-
Net cash provided by (used in) financing activities		111,187			(10,455	)
Decrease in cash		(28,252	)		(28,251	)
Cash - beginning of period		64,325			46,245
Cash – end of period	$	36,073		$	17,994
Supplemental disclosure of cash flow information:
Cash paid for interest	$	526		$	579
Cash paid for income taxes	$	500		$	--
Noncash financing activities:
Issuance of 588,236 shares of common stock as settlement of accrued compensation and other related costs	$	225,627		$	--
Issuance of 279,412 shares of common stock as settlement of certain accounts payable – related party	$	95,000		$	--
Issuance of 50,000 shares of common stock as settlement of certain accounts payable for director fees	$	17,000		$	--
Issuance of 193,454 shares of common stock as payment of interest due on convertible debentures	$	40,000		$	--
Issuance of 36,477 shares of common stock as payment of offering costs related to private placements	$	12,534		$	--
Issuance of 55,237 shares of common stock as payment of $50,000 of principal and $3,729 of interest due on convertible debentures	$	-		$	53,729
Issuance of notes payable as payment for insurance premiums	$	20,220		$	15,867

The accompanying notes are an integral part of these financial statements.

4

Scivanta Medical Corporation

Notes to the Unaudited Financial Statements

1. Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses and negative cash flows from operations.  The Company had a working capital deficiency of $623,916 and an accumulated deficit of $23,714,735 as of July 31, 2013.  The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative.  The Company has reduced operating expenses and, effective November 1, 2011, each of the Company’s officers agreed to waive the annual base salary due to them and each of the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors.

On January 23, 2013, the Company issued shares of its common stock as settlement of $225,627 of accrued compensation due through October 31, 2011 to its officers and other related costs, $17,000 of fees due through October 31, 2011 to its current independent directors and a former independent director and $95,000 due for office rent through January 31, 2013 ($80,000 accrued as of October 31, 2012).  The Company has also deferred certain other vendor payments until the Company secures sufficient additional financing.

While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to our stockholders.

2. Amendment to Restated Articles of Incorporation

Effective April 22, 2013, the Company amended its Restated Articles of Incorporation to, among other items, effectuate a 10-for-1    reverse stock split (the “Reverse Stock Split”) with respect to its outstanding shares of common stock and increase the amount of authorized capital stock to 520,000,000 shares, notwithstanding the effect of the Reverse Stock Split, consisting of 500,000,000 shares of common stock, par value $.001 per share, and 20,000,000 shares of preferred stock, par value $.001 per share.  All references in the accompanying financial statements to the number of shares outstanding and per-share amounts have been restated to reflect the Reverse Stock Split.  In connection with the amendments to the Restated Articles of Incorporation, the par value of the Company’s common stock remained $.001 per share, resulting in a reclassification between common stock and additional paid-in capital in order to account for the Reverse Stock Split.

5

3. Amended and Restated SCMS License Agreement

On February 14, 2011, the Company entered into an Amended and Restated Technology License Agreement (the “License Agreement”) with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren (“Lundgren”).  The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor”.  The License Agreement was amended on March 14, 2013 (the “Amendment”).

Pursuant to the License Agreement, the Licensor has granted Scivanta the exclusive world-wide rights to develop, manufacture and distribute the Scivanta Cardiac Monitoring System (the “SCMS”), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The term of the License Agreement ends on the later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.

Under the License Agreement, Scivanta made a cash payment of $30,000 to Hickey on June 3, 2011 and was required to make a cash payment of $105,000 to Hickey on July 31, 2012.  Pursuant to the Amendment, the $105,000 payment was restructured as follows:  (a)  $50,000 is due to Hickey on or before a date that is thirty (30) days after the closing of any single financing by the Company of at least $3,000,000 or any series of financings by the Company within a six (6) month period totaling at least $3,000,000; and (b) $55,000 is due to Hickey on or before the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology.  As of July 31, 2013 and October 31, 2012, the Company recorded the $105,000 due to Hickey as a non-current note payable.  

In addition, pursuant to the Amendment, the Company agreed to issue shares of its common stock to the Licensor with a value equal to $130,000 on the date the Company files for approval to market and sell a product utilizing the licensed technology.  The Company also agreed to issue shares of its common stock to the Licensor with a value equal to $160,000 on the date the Company receives approval to market and sell a product utilizing the licensed technology.The number of shares of the Company’s common stock to be issued to the Licensor will be calculated based on the market price of the Company’s common stock, as defined in the Amendment, on the date that each of the respective above noted events occur.

Scivanta is required to pay the Licensor a royalty of 5% of annual net sales, as defined in the License Agreement, subject to certain reductions as detailed in the License Agreement.  Beginning with the first full year of sales of the SCMS in the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales in the United States will be credited.  Further, beginning with the first full year of sales of the SCMS outside the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales outside the United States will be credited.  The Company is also required to pay the Licensor 25% of all sublicensing revenue, as defined in the License Agreement, received by the Company in connection with the Company’s sublicense of the rights granted to the Company under the License Agreement.

6

The License Agreement, as amended by the Amendment, also requires Scivanta to use commercially reasonable efforts to develop and market the SCMS within certain timeframes, subject to specified exceptions.  If Scivanta materially fails to perform any covenant, condition or undertaking of the License Agreement, including the failure to make any payments when due, the Licensor may give written notice of such default to Scivanta.  If Scivanta should fail to cure such default within ninety (90) days of notice of such default, then the Licensor, at its option, may terminate the License Agreement.  Further, the License Agreement contains standard provisions regarding indemnification and patent prosecution.

4. Related Party Transactions

David R. LaVance, the Company’s President and Chief Executive Officer, and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (“Century Capital”).   Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capital’s existing offices.  In addition, the Company rents office furniture and other equipment from Century Capital.  The sublease agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000.  The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes.

During the three and nine months ended July 31, 2013, the Company was billed $24,905 and $59,662, respectively, pursuant to the terms of the sublease agreement.  As of July 31, 2013, the Company owed Century Capital $30,000 for rent and $27,389 for other expenses, which is included in accounts payable – related party.  During the three and nine months ended July 31, 2012, the Company was billed $17,730 and $54,297, respectively, pursuant to the terms of the sublease agreement.

5. Notes Payable

Note Payable – IPFS

On March 20, 2013, the Company entered into a finance agreement with IPFS Corporation (“IPFS”).  Pursuant to the terms of this finance agreement, IPFS loaned the Company the principal amount of $20,220, which amount would accrue interest at a rate of 9.3% per annum, in order to partially fund the payment of the premium of the Company’s director and officer liability insurance.  The finance agreement requires the Company to make nine monthly payments of $2,335, including interest, commencing April 13, 2013.  For the three and nine months ended July 31, 2013, the Company recorded a total of $229 and $526, respectively, of interest expense related to this finance agreement.  As of July 31, 2013, the outstanding principal balance related to this finance agreement was $11,407.

7

6. Convertible Debentures

February 2007 Convertible Debentures

On February 8, 2007, the Company closed on a private placement of 8% convertible debentures dated February 1, 2007 (the “February 2007 Debentures”).  The gross proceeds received in connection with this private placement were $250,000.  The February 2007 Debentures originally had a three year term, maturing on January 31, 2010.  In January 2010, the holders agreed to a new maturity date of January 31, 2012, extending the term of the February 2007 Debentures for an additional two year period.

On January 11, 2012, the Company issued 50,000 shares of common stock at $1.00 per share as full payment of $50,000 of outstanding principal on certain February 2007 Debentures and 5,237 shares of common stock at per share prices ranging between $0.70 and $0.80 as full payment of $3,729 of accrued and unpaid interest related to those February 2007 Debentures.  Due to the reduction in the conversion price, the Company recorded a loss on conversion of these February 2007 Debentures of $21,750.

Effective January 31, 2012, certain holders of the February 2007 Debentures with an aggregate outstanding principal amount of $175,000, agreed to amend such February 2007 Debentures by extending the maturity date to January 31, 2014.  In addition, effective January 31, 2012, a holder of a February 2007 Debenture with an outstanding principal amount of $25,000 agreed to amend his February 2007 Debenture by extending the maturity date to July 31, 2012.  The Company has not made payment on this February 2007 Debenture and, as a result, such obligation can be placed in default by the holder.

For the three and nine months ended July 31, 2013, the Company recorded a total of $4,033 and $11,867, respectively, of interest expense related to the February 2007 Debentures.  For the three and nine months ended July 31, 2012, the Company recorded a total of $4,033 and $12,764, respectively, of interest expense related to the February 2007 Debentures.  As of July 31, 2013, $7,935 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expense.  As of July 31, 2013, the Company recorded the $200,000 of outstanding principal due on the February 2007 Debentures as a component of current convertible debentures.

May 2011 Convertible Debenture

On May 20, 2011, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “May 2011 Debenture”).  The May 2011 Debenture has a three year term maturing on May 20, 2014 and bears interest at a rate of 8% per annum.  For the three and nine months ended July 31, 2013, the Company recorded a total of $2,017 and $5,985, respectively, of interest expense related to the May 2011 Debenture.  For the three and nine months ended July 31, 2012, the Company recorded a total of $2,017 and $6,006, respectively, of interest expense related to the May 2011 Debenture.  As of July 31, 2013, $9,603 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses.  As of July 31, 2013, the Company recorded the $100,000 of outstanding principal due on the May 2011 Debenture as a component of current convertible debentures.

8

August 2012 Convertible Debenture

On August 15, 2012, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “August 2012 Debenture”).  The August 2012 Debenture has a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum.  For the three and nine months ended July 31, 2013, the Company recorded a total of $2,017 and $6,051, respectively, of interest expense related to the August 2012 Debenture.  As of July 31, 2013, $7,783 of interest due on the August 2012 Debenture was accrued and is included as a component of accrued expenses.  As of July 31, 2013, the Company recorded the $100,000 of outstanding principal due on the August 2012 Debenture as a component of non-current convertible debenture.

7. Stock-Based Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification 718, “Stock Compensation” (“ASC” 718”).  During the three and nine months ended July 31, 2013, the Company did not record any employee stock-based compensation expense.  During the three and nine months ended July 31, 2012, the Company recorded employee stock-based compensation expense of $0 and $3,716, respectively, which amounts were included in general and administrative expense.

The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and Topic 505-50, “Equity-Based Payments to Non-Employees.”   During the three and nine months ended July 31, 2013, the Company recorded non-employee stock-based compensation expense of $0 and $4,725, respectively, which amounts were included in general and administrative expense.  During the three and nine months ended July 31, 2012, the Company did not record any non-employee stock-based compensation expense.

8. Net Loss Per Common Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

9

For the three and nine months ended July 31, 2013, diluted net loss per share did not include the effect of 241,432 shares of common stock issuable upon the exercise of outstanding options, 32,000 shares of common stock issuable upon the exercise of outstanding warrants and 666,667 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

For the three and nine months ended July 31, 2012, diluted net loss per share did not include the effect of 249,532 shares of common stock issuable upon the exercise of outstanding options, 93,000 shares of common stock issuable upon the exercise of outstanding warrants and 416,667 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

9. Stockholders’ Equity

Stock Option Plans

The Company currently has two stock option plans in place:  the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).  The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002.  The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 200,000.  As of July 31, 2013, options to purchase 147,000 shares of the Company’s common stock were outstanding under the 2002 Equity Incentive Plan.  As a result of the adoption of the Company’s 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.

On May 31, 2007, the stockholders approved the Company’s 2007 Equity Incentive Plan.  The 2007 Equity Incentive Plan was placed into effect in order to encourage and enable employees and directors of the Company to acquire or increase their holdings of the Company’s common stock and to promote these individuals’ interests in the Company thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2007 Equity Incentive Plan provides for awards in the form of restricted shares, incentive stock options, non-qualified stock options and stock appreciation rights.  The aggregate number of shares of common stock which may be awarded under the 2007 Equity Incentive Plan is 300,000, subject to adjustment as provided in the 2007 Equity Incentive Plan.  As of July 31, 2013, options to purchase 94,432 shares of the Company’s common stock were outstanding under the 2007 Equity Incentive Plan and up to 205,568 shares of the Company’s common stock remain available for awards under the 2007 Equity Incentive Plan.

Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant.  Stock options granted and outstanding include only non-qualified stock options and vest over a period of up to five years and have a maximum term of ten years from the date of grant.

10

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2013 is as follows:

	Stock Option  Shares			Weighted Average  Exercise Price Per Common Share		Aggregate  Intrinsic Value
Outstanding at October 31, 2012		249,532		$	1.57	$	700
Granted during the period		--			--
Exercised during the period		--			--
Expired during the period		(8,100	)	$	1.40
Outstanding at July 31, 2013		241,432		$	1.57	$	--
Exercisable at July 31, 2013		241,432		$	1.57	$	--
Exercisable at October 31, 2012		249,532		$	1.57	$	700

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2013 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number ofShares Available for Purchase Under Outstanding Stock Options		Weighted  Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.20		3,500	$	0.20		1.4		3,500	$	0.20		1.4
$	0.80		33,500	$	0.80		1.1		33,500	$	0.80		1.1
$	1.40		94,432	$	1.40		4.6		94,432	$	1.40		4.6
$	2.00		110,000	$	2.00		3.5		110,000	$	2.00		3.5
			241,432	$	1.57		3.5		241,432	$	1.57		3.5

11

Warrants to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2013 is as follows:

	Warrant Shares			Weighted Average  Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2012		93,000		$	1.19	$	--
Issued during the period		--			--
Exercised during the period		--			--
Expired during the period		(61,000	)	$	1.29
Outstanding at July 31, 2013		32,000		$	1.00	$	--
Exercisable at July 31, 2013		32,000		$	1.00	$	--
Exercisable at October 31, 2012		93,000		$	1.19	$	--

Information with respect to warrants outstanding and warrants exercisable at July 31, 2013 is as follows:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average  Exercise Price Per Common  Share		Weighted Average Remaining Contractual  Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common  Share		Weighted Average Remaining Contractual Life (Years)
$	0.40		20,000	$	0.40		0.8		20,000	$	0.40		0.8
$	2.00		12,000	$	2.00		0.3		12,000	$	2.00		0.3
			32,000	$	1.00		0.6		32,000	$	1.00		0.6

12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Background

Scivanta is a Nevada corporation headquartered in Spring Lake, New Jersey.  Scivanta currently does not sell any products, technologies or services.

On November 10, 2006, we acquired the exclusive world-wide rights to develop, manufacture and distribute the SCMS, a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The SCMS is currently in the development stage; however, since the end of fiscal 2009 all development activity has ceased as we attempt to raise additional financing.

The SCMS will provide the primary measurements of cardiac performance, including left atrial pressure, which is a crucial measurement in monitoring cardiac challenged patients.  The essential hardware, software and catheter components for the SCMS have been completed.  Scivanta currently has a fully assembled SCMS device that has been used in the initial clinical trial.  The two major items remaining in the development of the SCMS are the completion of the clinical trials and the design and engineering of the production model of the SCMS.

We will not be able to complete the clinical trials or the design and engineering of the production model of the SCMS without obtaining additional cash through equity and/or debt financing or through corporate partnerships.  We continue to pursue potential investors and from time to time engage placement agents to assist us in this endeavor.  No assurances can be given that we will be able to obtain sufficient capital to finish the development of the SCMS through any corporate partnerships and/or through equity and/or debt financing.  In addition, no assurances can be given that if we successfully develop and market the SCMS, such product will become profitable.

In addition to developing the SCMS, our strategy for business development, if sufficient funding is obtained, will focus on the acquisition, through licensing or purchasing, of technologies, products or businesses that are sold or are capable of being sold in a specialty or niche market.  Technologies, products or businesses of interest include, but are not limited to, medical devices, pharmaceuticals and other proprietary technologies, patented products or businesses.  The Company believes that specialty or niche-market technologies, products or businesses generally offer attractive operating margins.  These products are distributed through specialty distributor networks, manufacturer representatives or other specialized channels to the original equipment manufacturer market, supplier and provider markets and to the general marketplace.

Critical Accounting Policies and Estimates

The discussion and analysis of the Company’s financial condition and results of operations are based upon the interim financial statements contained elsewhere herein, which have been prepared in accordance with U.S. GAAP.  The preparation of these financial statements required us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.  On an on-going basis, we evaluate our estimates, including those related to income taxes and contingencies and litigation.  We based our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.

The critical accounting estimates that we believe affect the more significant judgments and estimates used in preparation of the financial statements contained elsewhere herein are described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Financial Statements included in the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2012.  There have been no material changes to the critical accounting policies.

13

Results of Operations

Research and Development.  For the three months ended July 31, 2013, research and development expenses were $3,115, as compared to $5,540, for the three months ended July 31, 2012.  The $2,425, or 44%, decrease in research and development expenses for the three months ended July 31, 2013 was due to a decrease in patent costs.  For the nine months ended July 31, 2013, research and development expenses were $3,115, as compared to $14,430 for the nine months ended July 31, 2012.  The $11,315, or 78%, decrease in research and development expense for the nine months ended July 31, 2013 was due to a decrease in patent costs.

The amount of research and development expense to be incurred by us during the fiscal year ending October 31, 2013 will depend upon our ability to secure additional capital through an equity and/or debt financing or corporate partnerships.  In the event that we are able to obtain additional capital sufficient to fund our research and development program, we would expect research and development expenses for the fiscal year ending October 31, 2013 to increase.  If we are unable to obtain additional capital sufficient to fund our research and development program, we would expect research and development expenses for the fiscal year ending October 31, 2013 to remain at the current level.

General and Administrative.  For the three months ended July 31, 2013, general and administrative expenses were $65,389, as compared to $62,209 for the three months ended July 31, 2012.  The $3,180, or 5%, increase in general and administrative expenses for the three months ended July 31, 2013 was primarily due to a $7,225 increase in office maintenance expenses, offset by a $5,000 decrease in audit related fees.

For the nine months ended July 31, 2013, general and administrative expenses were $260,551, as compared to $180,562 for the nine months ended July 31, 2012.  The $79,989, or 44%, increase in general and administrative expenses for the nine months ended July 31, 2013 was primarily due to a $57,730 increase in legal expenses related to the Company’s amendment to its Restated Articles of Incorporation and our review of potential acquisitions, a $17,000 increase in consulting fees related to our review of potential acquisitions and financings and a $10,063 increase in costs associated with mailings to stockholders and related SEC filings regarding the amendment to our Restated Articles of Incorporation, offset by a $10,000 decrease in audit related fees.

The amount of general and administrative expense to be incurred by us during the fiscal year ending October 31, 2013 will depend upon our ability to secure additional capital through an equity and/or debt financing or corporate partnerships.  In the event that we are able to obtain additional capital sufficient to fund our development and marketing of the SCMS and to pursue the acquisition of other technologies, products or businesses, we would expect general and administrative expenses for the fiscal year ending October 31, 2013 to increase as we build the administrative infrastructure necessary to support the development and marketing of the SCMS and any other technology, product or business acquired by us.  If we are unable to obtain additional capital sufficient to fund our development and marketing of the SCMS or to acquire other technologies, products or businesses, we would expect general and administrative expenses for the fiscal year ending October 31, 2013 to decrease as we continue to reduce our operating activities.

14

Interest Expense.  For the three months ended July 31, 2013, interest expense was $8,296, as compared to $6,217 for the three months ended July 31, 2012.  The $2,079, or 33%, increase in interest expense for the three months ended July 31, 2013 was primarily due to $2,017 of interest associated with the August 2012 Debenture.

For the nine months ended July 31, 2013, interest expense was $24,429, as compared to $19,349 for the nine months ended July 31, 2012.  The $5,080, or 26%, increase in interest expense for the nine months ended July 31, 2013 was primarily due to $6,051 of interest associated with the August 2012 Debenture, offset by a $897 decrease in interest associated with the February 2007 Debentures resulting from the conversion to common stock of a portion of the outstanding aggregate principal of the February 2007 Debentures in January 2012.

Loss on Conversion of Convertible Debentures.  During the nine months ended July 31, 2012, we recognized a loss of $21,750 on the conversion of certain February 2007 Debentures resulting from a reduction in the conversion price.

Net Loss.  For the three months ended July 31, 2013, our net loss was $76,800, or $0.01 per share (basic and diluted), as compared to a net loss of $73,966, or $0.02 per share (basic and diluted), for the three months ended July 31, 2012.  The $2,834, or 4%, increase in the net loss for the three months ended July 31, 2013 was primarily attributable to a $3,180 increase in general and administrative expenses and a $2,079 increase in interest expense, offset by a $2,425 decrease in research and development expenses.

For the nine months ended July 31, 2013, our net loss was $288,095, or $0.06 per share (basic and diluted), as compared to a net loss of $236,091, or $0.08 per share (basic and diluted), for the nine months ended July 31, 2012.  The $52,004, or 22%, increase in the net loss for the nine months ended July 31, 2013 was primarily attributable to a $79,989 increase in general and administrative expenses and a $5,080 increase interest expense, offset by a $21,750 decrease in the loss on conversion of convertible debentures and a $11,315 decrease in research and development expenses.

Liquidity and Capital Resources

As of July 31, 2013, the Company had a working capital deficiency of $623,916 and cash on hand of $36,073.  The $28,252 decrease in cash on hand from October 31, 2012 was primarily due to the Company’s continuing operating expenses, offset by the receipt of $120,000 of net proceeds in connection with the sale of an aggregate of 1,136,362 shares of the Company’s common stock that occurred in January and April 2013.

During the past several years, the Company has generally sustained recurring losses and negative cash flows from operations.  We currently do not generate any revenue from operations.  The Company’s operations most recently have been funded through a combination of the sale of our convertible debentures and common stock and through the issuance of our common stock in exchange for services.

15

On January 23, 2013, the Company issued an aggregate of 588,236 shares of its common stock as settlement of $225,627 of accrued compensation due through October 31, 2011 to its officers and other related costs, issued an aggregate of 50,000 shares of its common stock as settlement of $17,000 of fees owed through October 31, 2011 to its current independent directors and a former independent director and issued 279,412 shares of its common stock to Century Capital as settlement of $95,000 of office rent owed by the Company through January 31, 2013 ($80,000 accrued as of October 31, 2012).

As of September 13, 2013, our cash position was approximately $26,000.  Without any additional financing, we will only be able to continue our administrative operations, on a limited basis, for approximately four months from the filing date of this quarterly report on Form 10-Q.  We have reduced operating expenses and effective November 1, 2011, Scivanta’s officers agreed to waive the annual base salary due to them and Scivanta’s directors agreed to waive the annual retainer and meeting fees due to them until Scivanta is able to raise sufficient capital that would provide Scivanta with the ability to pay cash compensation to its officers and directors.  Scivanta has also deferred certain vendor payments until it secures sufficient additional financing.  Our independent registered public accounting firm included an emphasis of a matter paragraph in its report included in our annual report on Form 10-K for the fiscal year ended October 31, 2012, which expressed substantial doubt about our ability to continue as a going concern.  Our financial statements included herein do not include any adjustments related to this uncertainty.

We currently do not have any lending relationships with commercial banks and do not anticipate establishing such relationships in the foreseeable future due to our limited operations and assets.  We believe that our focus should be on obtaining additional capital through the private placement of our securities.  We are pursuing potential equity and/or debt investors and have from time to time engaged placement agents to assist us in this initiative.  While we are pursuing the opportunities and actions described above, there can be no assurance that we will be successful in our efforts.  If we are unable to secure additional capital, we will explore other strategic alternatives, including, but not limited to, the sale of Scivanta.  Any additional equity financing may result in substantial dilution to our stockholders.

Expenditures related to the development of the SCMS are at our discretion.  Assuming that we are successful in obtaining additional financing, we estimate that we could potentially spend approximately $1,000,000 related to the development of the SCMS over the twelve month period following the financing.

16

Item 3.               Quantitative and Qualitative Disclosures About Market Risk

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 4.               Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, as of the end of the period covered by this quarterly report on Form 10-Q, the Company carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures.  This evaluation was carried out under the supervision and with the participation of the Company’s management, including the Company’s President and Chief Executive Officer and the Company’s Executive Vice President, Chief Financial Officer and Secretary, who concluded that the Company’s disclosure controls and procedures are effective.  There has been no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

17

PART II.  OTHER INFORMATION

Item 1.               Legal Proceedings

None.

Item 1A.            Risk Factors

Scivanta is a smaller reporting company and is therefore not required to provide this information.

Item 2.               Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.               Defaults Upon Senior Securities

Not Applicable.

Item 4.               Mine Safety Disclosures

Not Applicable.

Item 5.               Other Information

None.

Item 6.               Exhibits

See Index of Exhibits Commencing on Page E-1.

18

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DATE:	SCIVANTA MEDICAL CORPORATION
September 16, 2013	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

September 16, 2013	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President, Chief Financial Officer and Secretary

19

INDEX OF EXHIBITS

Exhibit Number	Description of Exhibit
3.1	Amended and Restated Articles of Incorporation of Scivanta Medical Corporation, (the “Company”), which was filed in the Office of the Secretary of State of the State of Nevada on April 22, 2013 (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2013).
3.2	Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).
4.1	Specimen stock certificate representing the Company’s common stock (incorporated by reference to Exhibit 4.1 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2006, filed with the SEC on January 29, 2007).
4.2	Form of Convertible Debenture, dated as of February 1, 2007, issued to the following persons and in the following amounts:  Jesse H. Austin, III ($50,000); Andrew O. Whiteman and Gwen C. Whiteman, JTWROS ($25,000); Jack W. Cumming ($25,000); Scott C. Withrow ($25,000); Terrence McQuade ($25,000); Steven J. Olsen ($25,000); and Marc G. Robinson and Joshua Goldfarb ($25,000) (incorporated by reference to Exhibit 4.8 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).
4.3	Form of Addendum to Convertible Debenture, dated as of January 31, 2010, issued to the persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.3 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2009, filed with the SEC on January 29, 2010).
4.4	Form of Addendum to Convertible Debenture, dated as of January 31, 2012, issued to certain persons set forth in Exhibit 4.2 (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended January 31, 2012, filed with the SEC on March 16, 2012).
4.5	8% Convertible Debenture, dated as of May 20, 2011, in the principal amount of $100,000 issued to Zanett Opportunity Fund, Ltd. (incorporated by reference to Exhibit 4.4 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2011, filed with the SEC on June 14, 2011).
4.6	8% Convertible Debenture, dated as of August 15, 2012, in the principal amount of $100,000 issued to Zanett Opportunity Fund, Ltd. (incorporated by reference to Exhibit 4.1 to the Company’s current report on Form 8-K filed with the SEC on August 21, 2012).

E-1

Exhibit Number	Description of Exhibit
10.1	The Company’s 2002 Equity Incentive Plan, adopted and effective January 1, 2002 (incorporated by reference to Exhibit B of the Company’s definitive proxy statement, filed with the SEC on June 10, 2002).
10.2	Sublease Agreement, dated February 1, 2007, between the Company and Century Capital Associates LLC (incorporated by reference to Exhibit 10.14 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).
10.3	Amended and Restated Technology License Agreement between the Company and The Research Foundation of State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated February 14, 2011 (incorporated by reference to Exhibit 10.8 to the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2010, filed with the SEC on February 15, 2011).
10.3.1	First Addendum to the Amended and Restated Technology License Agreement between the Company and The Research Foundation for State University of New York for and on behalf of University of Buffalo, and Donald D. Hickey, M.D. and Clas E. Lundgren dated March 14, 2013 (incorporated by reference to Exhibit 10.3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended January 31, 2013, filed with the SEC on March 18, 2013).
10.4	Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.16 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).
10.5	Stock Option Agreement and Notice of Grant, dated February 5, 2007, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 500,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.17 to the Company’s quarterly report on Form 10-QSB for the quarter ended January 31, 2007, filed with the SEC on March 14, 2007).
10.6	Company’s 2007 Equity Incentive Plan, adopted and effective May 31, 2007 (incorporated by reference to Appendix to the Company’s definitive proxy statement, filed with the SEC on April 27, 2007).
10.7	Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.21 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).
10.8	Stock Option Agreement and Notice of Grant, dated January 1, 2008, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 100,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.22 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).

E-2

Exhibit Number	Description of Exhibit
10.9	Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.26 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).
10.10	Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.27 to the Company’s current report on Form 8-K filed with the SEC on January 2, 2008).
10.11	Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.27 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).
10.12	Amendment No. 1 dated as of June 18, 2010 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.28 to the Company’s quarterly report on Form 10-Q for the quarter ended April 30, 2010, filed with the SEC on June 21, 2010).
10.13	Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and David R. LaVance (incorporated by reference to Exhibit 10.23 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).
10.14	Amendment No. 2 dated as of January 3, 2012 to the Executive Employment Agreement, dated as of January 1, 2008, between the Company and Thomas S. Gifford (incorporated by reference to Exhibit 10.24 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2011, filed with the SEC on January 30, 2012).
10.15	Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which David R. LaVance was granted a non-qualified stock option to purchase up to 25,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.32 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).
10.16	Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Thomas S. Gifford was granted a non-qualified stock option to purchase up to 25,000 shares of common stock of the Company (incorporated by reference to Exhibit 10.33 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).
10.17	Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Lawrence M. Levy was granted a non-qualified stock option to purchase up to 3,500 shares of common stock of the Company (incorporated by reference to Exhibit 10.35 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).

E-3

Exhibit Number	Description of Exhibit
10.18	Stock Option Agreement and Notice of Grant, dated January 21, 2009, pursuant to which Anthony Giordano, III was granted a non-qualified stock option to purchase up to 3,900 shares of common stock of the Company (incorporated by reference to Exhibit 10.36 to the Company’s annual report on Form 10-KSB for the fiscal year ended October 31, 2008, filed with the SEC on January 29, 2009).
31.1	Section 302 Certification of Chief Executive Officer.
31.2	Section 302 Certification of Chief Financial Officer.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
101*	The following materials from the Company’s quarterly report on Form 10-Q for the period ended July 31, 2013, formatted in Extensible Business Reporting Language (XBRL):  (i) balance sheets; (ii) statements of operations; (iii) statements of cash flows; and (iv) notes to the financial statements.

*  Pursuant to Rule 406T of Regulation S-T, the interactive data files included as Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 E-4

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, David R. LaVance, certify that:

1. I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:   September 16, 2013	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Thomas S. Gifford, certify that:

1.I have reviewed this report on Form 10-Q of Scivanta Medical Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:   September 16, 2013	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President, Chief Financial Officer and Secretary

EX-32.1

 EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2013, as filed with the Securities and Exchange Commission (the “Report”), I, David R. LaVance, President and Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)           the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2)           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:   September 16, 2013	By:	/s/ David R. LaVance
		David R. LaVance
		President and Chief Executive Officer

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scivanta Medical Corporation (the “Company”) on Form 10-Q for the period ended July 31, 2013, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas S. Gifford, Executive Vice President, Chief Financial Officer and Secretary of the Company, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)           the Report fully complies with the requirements of §13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. §78m or 78o(d), and,

(2)           the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:   September 16, 2013	By:	/s/ Thomas S. Gifford
		Thomas S. Gifford
		Executive Vice President, Chief Financial Officer and Secretary

XML

Basis of Presentation (Details) (USD $)	0 Months Ended
	Jan. 23, 2013	Jul. 31, 2013	Oct. 31, 2012
Basis of Presentation (Textual)
Working Capital Deficiency		$ 623,916
Accumulated deficit		(23,714,735)	(23,426,640)
Value of common stock issued as full payment of accrued compensation due to its officers	225,627
Issuance of common stock in payment of fee to its current independent directors and a former independent director	17,000
Issuance of common stock in payment of office rent	95,000
Accrued rent			$ 80,000

XML

Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012
Statements Of Operations [Abstract]
Revenue
Operating expenses:
Research and development	3,115	5,540	3,115	14,430
General and administrative	65,389	62,209	260,551	180,562
Loss from operations	(68,504)	(67,749)	(263,666)	(194,992)
Interest expense	(8,296)	(6,217)	(24,429)	(19,349)
Loss on conversion of convertible debentures				(21,750)
Net loss	$ (76,800)	$ (73,966)	$ (288,095)	$ (236,091)
Net loss per common share, basic and diluted	$ (0.01)	$ (0.02)	$ (0.06)	$ (0.08)
Weighted average number of common shares outstanding, basic and diluted	5,429,384	3,111,691	4,494,496	3,098,337

XML

Related Party Transactions

9 Months Ended

Jul. 31, 2013

Related Party Transactions [Abstract]

Related Party Transactions

4. Related Party Transactions

David R. LaVance, the Company’s President and Chief Executive Officer, and Thomas S. Gifford, the Company’s Executive Vice President, Chief Financial Officer and Secretary, are principals of Century Capital Associates LLC (“Century Capital”).   Effective February 1, 2007, the Company and Century Capital entered into a sublease agreement pursuant to which the Company rents office space approximating 2,000 square feet inside Century Capital’s existing offices.  In addition, the Company rents office furniture and other equipment from Century Capital.  The sublease agreement has a month to month term that requires sixty days written notice to terminate and a monthly rental fee of $5,000.  The Company is responsible for all operating costs associated with the office space, including utilities, maintenance and property taxes.

During the three and nine months ended July 31, 2013, the Company was billed $24,905 and $59,662, respectively, pursuant to the terms of the sublease agreement.  As of July 31, 2013, the Company owed Century Capital $30,000 for rent and $27,389 for other expenses, which is included in accounts payable – related party.  During the three and nine months ended July 31, 2012, the Company was billed $17,730 and $54,297, respectively, pursuant to the terms of the sublease agreement.

XML

Net Loss Per Common Share (Details)	3 Months Ended		9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012
Stock Options [Member]
Net Loss Per Common Share (Textual)
Anti-dilutive shares which were not included in computation of diluted per share	241,432	249,532	241,432	249,532
Warrant [Member]
Net Loss Per Common Share (Textual)
Anti-dilutive shares which were not included in computation of diluted per share	32,000	93,000	32,000	93,000
Convertible Debt Securities [Member]
Net Loss Per Common Share (Textual)
Anti-dilutive shares which were not included in computation of diluted per share	666,667	416,667	666,667	416,667

XML

Amendment to Restated Articles of Incorporation (Details) (USD $)	1 Months Ended
	Apr. 22, 2013	Jul. 31, 2013	Oct. 31, 2012
Amendment to Restated Articles of Incorporation (Textual)
Reverse stock split ratio	10-for-1
Authorized capital stock	520,000,000
Common stock, shares authorized	500,000,000	500,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000	20,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001

XML

Stockholders' Equity (Details 2) (Warrant [Member], USD $)	9 Months Ended
	Jul. 31, 2013
Warrant [Member]
Summary of warrant transactions
Stock Option/Warrants Shares, Outstanding Beginning Balance	93,000
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance	$ 1.19
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants beginning balance
Stock Option/Warrants, Granted during the period
Weighted Average Exercise Price Per Common Share/Warrants, Granted during the period
Stock Option/Warrants, Exercised during the period
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period
Stock Option/Warrants, Expired during the period	(61,000)
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period	$ 1.29
Stock Option/Warrants Outstanding, Balance	32,000
Weighted Average Exercise Price Per Common Share/Warrants Outstanding, Balance	$ 1.00
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Balance
Stock Option Shares/Warrants, Exercisable at July 31,2013	32,000
Weighted Average Exercise Price Per Common Share/Warrants, Exercisable at July 31,2013	$ 1.00
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at July 31,2013
Stock Option/Warrants, Exercisable at October 31, 2012	93,000
Weighted Average Exercise Price Per Common Share/Warrant, Exercisable at October 31, 2012	$ 1.19
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at October 31, 2012

XML

Stockholders' Equity (Details 1) (Stock Option [Member], USD $)	9 Months Ended
	Jul. 31, 2013	Oct. 31, 2012
Schedule of outstanding and exercisable options and warrants
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	241,432
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 1.57
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	241,432	249,532
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 1.57	$ 1.57
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	3 years 6 months
0.20 [Member]
Schedule of outstanding and exercisable options and warrants
Exercise Price	$ 0.20
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	3,500
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.20
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 4 months 24 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	3,500
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.20
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	1 year 4 months 24 days
0.80 [Member]
Schedule of outstanding and exercisable options and warrants
Exercise Price	$ 0.80
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	33,500
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.80
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 1 month 6 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	33,500
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.80
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	1 year 1 month 6 days
1.40 [Member]
Schedule of outstanding and exercisable options and warrants
Exercise Price	$ 1.40
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	94,432
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 1.40
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 7 months 6 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	94,432
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 1.40
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	4 years 7 months 6 days
2.00 [Member]
Schedule of outstanding and exercisable options and warrants
Exercise Price	$ 2.00
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	110,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 2.00
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	3 years 6 months
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	110,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 2.00
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	3 years 6 months

XML

Stockholders' Equity (Details) (Stock Option [Member], USD $)	9 Months Ended
	Jul. 31, 2013
Stock Option [Member]
Summary of stock option transactions for employees and directors under the Equity Incentive Plans
Stock Option/Warrants Shares, Outstanding Beginning Balance	249,532
Weighted Average Exercise Price Per Common Share/Warrants, Outstanding Beginning Balance	$ 1.57
Aggregate Intrinsic Value, Outstanding Stock Option/Warrants beginning balance	$ 700
Stock Option/Warrants, Granted during the period
Weighted Average Exercise Price Per Common Share/Warrants, Granted during the period
Stock Option/Warrants, Exercised during the period
Weighted Average Exercise Price Per Common Share/Warrants, Exercised during the period
Stock Option/Warrants, Expired during the period	(8,100)
Weighted Average Exercise Price Per Common Share/Warrants, Expired during the period	$ 1.40
Stock Option/Warrants Outstanding, Balance	241,432
Weighted Average Exercise Price Per Common Share/Warrants Outstanding, Balance	$ 1.57
Aggregate Intrinsic Value Outstanding Stock Option/Warrants, Balance
Stock Option Shares/Warrants, Exercisable at July 31,2013	241,432
Weighted Average Exercise Price Per Common Share/Warrants, Exercisable at July 31,2013	$ 1.57
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at July 31,2013
Stock Option/Warrants, Exercisable at October 31, 2012	249,532
Weighted Average Exercise Price Per Common Share/Warrant, Exercisable at October 31, 2012	$ 1.57
Aggregate Intrinsic Value, Stock Option/Warrants Exercisable at October 31, 2012	$ 700

XML

Statements of Cash Flows (Unaudited) (Parenthetical) (USD $)	9 Months Ended
	Jul. 31, 2013
Statements Of Cash Flows [Abstract]
Common stock shares issued as payment of accrued compensation and other related costs	588,236
Common stock shares issued as payment of certain accounts payable related party	279,412
Common stock shares issued as payment of certain accounts payable for director fees	50,000
Common stock shares issued as payment for interest due on convertible debentures	193,454
Common stock shares issued as payment of offering costs related to private placements	36,477
Shares issued as payment of principal and interest on convertible debentures	55,237
Principal value of convertible debentures	$ 50,000
Interest on convertible debentures	$ 3,729

XML

Amendment to Restated Articles of Incorporation

9 Months Ended

Jul. 31, 2013

Amendment To Restated Articles Of Incorporation [Abstract]

Amendment to Restated Articles of Incorporation

2. Amendment to Restated Articles of Incorporation

Effective April 22, 2013, the Company amended its Restated Articles of Incorporation to, among other items, effectuate a 10-for-1    reverse stock split (the “Reverse Stock Split”) with respect to its outstanding shares of common stock and increase the amount of authorized capital stock to 520,000,000 shares, notwithstanding the effect of the Reverse Stock Split, consisting of 500,000,000 shares of common stock, par value $.001 per share, and 20,000,000 shares of preferred stock, par value $.001 per share.  All references in the accompanying financial statements to the number of shares outstanding and per-share amounts have been restated to reflect the Reverse Stock Split.  In connection with the amendments to the Restated Articles of Incorporation, the par value of the Company’s common stock remained $.001 per share, resulting in a reclassification between common stock and additional paid-in capital in order to account for the Reverse Stock Split.

XML

Note Payable

9 Months Ended

Jul. 31, 2013

Notes Payable and Convertible Debentures [Abstract]

Notes Payable

5. Notes Payable

Note Payable – IPFS

On March 20, 2013, the Company entered into a finance agreement with IPFS Corporation (“IPFS”).  Pursuant to the terms of this finance agreement, IPFS loaned the Company the principal amount of $20,220, which amount would accrue interest at a rate of 9.3% per annum, in order to partially fund the payment of the premium of the Company’s director and officer liability insurance.  The finance agreement requires the Company to make nine monthly payments of $2,335, including interest, commencing April 13, 2013.  For the three and nine months ended July 31, 2013, the Company recorded a total of $229 and $526, respectively, of interest expense related to this finance agreement.  As of July 31, 2013, the outstanding principal balance related to this finance agreement was $11,407.

XML

Amended and Restated SCMS License Agreement

9 Months Ended

Jul. 31, 2013

Amended and Restated Scms License Agreement Disclosure [Abstract]

Amended and Restated SCMS License Agreement

3. Amended and Restated SCMS License Agreement

On February 14, 2011, the Company entered into an Amended and Restated Technology License Agreement (the “License Agreement”) with The Research Foundation of State University of New York, for and on behalf of the University at Buffalo (the “Foundation”), Donald D. Hickey, M.D. (“Hickey”) and Clas E. Lundgren (“Lundgren”).  The Foundation, Hickey and Lundgren shall be collectively referred to herein as the “Licensor”.  The License Agreement was amended on March 14, 2013 (the “Amendment”).

Pursuant to the License Agreement, the Licensor has granted Scivanta the exclusive world-wide rights to develop, manufacture and distribute the Scivanta Cardiac Monitoring System (the “SCMS”), a minimally invasive two-balloon esophageal catheter system used to monitor cardiac performance.  The term of the License Agreement ends on the later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.

Under the License Agreement, Scivanta made a cash payment of $30,000 to Hickey on June 3, 2011 and was required to make a cash payment of $105,000 to Hickey on July 31, 2012.  Pursuant to the Amendment, the $105,000 payment was restructured as follows:  (a)  $50,000 is due to Hickey on or before a date that is thirty (30) days after the closing of any single financing by the Company of at least $3,000,000 or any series of financings by the Company within a six (6) month period totaling at least $3,000,000; and (b) $55,000 is due to Hickey on or before the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology.  As of July 31, 2013 and October 31, 2012, the Company recorded the $105,000 due to Hickey as a non-current note payable.  

In addition, pursuant to the Amendment, the Company agreed to issue shares of its common stock to the Licensor with a value equal to $130,000 on the date the Company files for approval to market and sell a product utilizing the licensed technology.  The Company also agreed to issue shares of its common stock to the Licensor with a value equal to $160,000 on the date the Company receives approval to market and sell a product utilizing the licensed technology.The number of shares of the Company’s common stock to be issued to the Licensor will be calculated based on the market price of the Company’s common stock, as defined in the Amendment, on the date that each of the respective above noted events occur.

Scivanta is required to pay the Licensor a royalty of 5% of annual net sales, as defined in the License Agreement, subject to certain reductions as detailed in the License Agreement.  Beginning with the first full year of sales of the SCMS in the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales in the United States will be credited.  Further, beginning with the first full year of sales of the SCMS outside the United States and for two years thereafter, Scivanta is required to pay an annual minimum royalty of $100,000 to the Licensor against which any royalty on net sales paid in the same calendar year for sales outside the United States will be credited.  The Company is also required to pay the Licensor 25% of all sublicensing revenue, as defined in the License Agreement, received by the Company in connection with the Company’s sublicense of the rights granted to the Company under the License Agreement.

The License Agreement, as amended by the Amendment, also requires Scivanta to use commercially reasonable efforts to develop and market the SCMS within certain timeframes, subject to specified exceptions.  If Scivanta materially fails to perform any covenant, condition or undertaking of the License Agreement, including the failure to make any payments when due, the Licensor may give written notice of such default to Scivanta.  If Scivanta should fail to cure such default within ninety (90) days of notice of such default, then the Licensor, at its option, may terminate the License Agreement.  Further, the License Agreement contains standard provisions regarding indemnification and patent prosecution.

XML

Stockholders' Equity (Details 3) (Warrant [Member], USD $)	9 Months Ended
	Jul. 31, 2013	Oct. 31, 2012
Schedule of outstanding and exercisable options and warrants
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	32,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 1.00
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	7 months 6 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	32,000	93,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 1.00	$ 1.19
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	7 months 6 days
0.40 [Member]
Schedule of outstanding and exercisable options and warrants
Range of Exercise Prices	$ 0.40
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	20,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 0.40
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	9 months 18 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	20,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 0.40
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	9 months 18 days
2.00 [Member]
Schedule of outstanding and exercisable options and warrants
Range of Exercise Prices	$ 2.00
Stock Options/ Warrants Outstanding, Number of Shares Available Under Outstanding Stock Options	12,000
Stock Options/ Warrants Outstanding, Weighted Average Exercise Price Per Common Share	$ 2.00
Stock Options/ Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	3 months 18 days
Stock Options/ Warrants Exercisable, Number of Shares Available for Purchase Under Outstanding Stock Options	12,000
Stock Options/ Warrants Exercisable, Weighted Average Exercise Price Per Common Share	$ 2.00
Stock Options/ Warrants Exercisable, Weighted Average Remaining Contractual Life (Years)	3 months 18 days

XML

Balance Sheets (Unaudited) (Parenthetical) (USD $)	Jul. 31, 2013	Oct. 31, 2012
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	10,000,000
Common stock, shares issued	5,429,384	3,111,691
Common stock, shares outstanding	5,429,384	3,111,691

XML

Net Loss Per Common Share

9 Months Ended

Jul. 31, 2013

Net Loss Per Common Share [Abstract]

Net Loss Per Common Share

8. Net Loss Per Common Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive.  The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

For the three and nine months ended July 31, 2013, diluted net loss per share did not include the effect of 241,432 shares of common stock issuable upon the exercise of outstanding options, 32,000 shares of common stock issuable upon the exercise of outstanding warrants and 666,667 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

For the three and nine months ended July 31, 2012, diluted net loss per share did not include the effect of 249,532 shares of common stock issuable upon the exercise of outstanding options, 93,000 shares of common stock issuable upon the exercise of outstanding warrants and 416,667 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

XML

Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Cash flows from operating activities:
Net loss	$ (288,095)	$ (236,091)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation expense	4,725	3,716
Loss on conversion of convertible debentures		21,750
Changes in operating assets and liabilities:
Grant receivable		131,979
Prepaid expenses	13,509	12,633
Accounts payable	71,281	18,881
Accounts payable - related party	69,738	25,566
Accrued expenses	(10,597)	3,770
Net cash used in operating activities	(139,439)	(17,796)
Cash flows from financing activities:
Repayment of notes payable	(8,813)	(10,455)
Proceeds from sale of common stock, net of offering costs	120,000
Net cash provided by (used in) financing activities	111,187	(10,455)
Decrease in cash	(28,252)	(28,251)
Cash - beginning of period	64,325	46,245
Cash - end of period	36,073	17,994
Supplemental disclosure of cash flow information:
Cash paid for interest	526	579
Cash paid for income taxes	500
Noncash financing activities:
Issuance of 588,236 shares of common stock as settlement of accrued compensation and other related costs	225,627
Issuance of 279,412 shares of common stock as settlement of certain accounts payable - related party	95,000
Issuance of 50,000 shares of common stock as settlement of certain accounts payable for director fees	17,000
Issuance of 193,454 shares of common stock as payment of interest due on convertible debentures	40,000
Issuance of 36,477 shares of common stock as payment of offering costs related to private placements	12,534
Issuance of 55,237 shares of common stock as payment of $50,000 of principal and $3,729 of interest due on convertible debentures		53,729
Issuance of notes payable as payment for insurance premiums	$ 20,220	$ 15,867

XML

Balance Sheets (Unaudited) (USD $)	Jul. 31, 2013	Oct. 31, 2012
Current assets:
Cash	$ 36,073	$ 64,325
Prepaid expenses	16,254	9,543
Total current assets	52,327	73,868
Current liabilities:
Accounts payable	277,126	222,845
Accounts payable - related party	57,389	82,651
Accrued expenses	30,321	90,043
Accrued compensation		225,627
Notes payable	11,407	105,000
Convertible debentures	300,000	25,000
Total current liabilities	676,243	751,166
Convertible debenture	100,000	375,000
Note payable	105,000
Total liabilities	881,243	1,126,166
Commitments
Stockholders' deficiency:
Preferred stock, $.001 par value; 20,000,000 shares authorized; no shares issued
Common stock, $.001 par value; 500,000,000 and 10,000,000 shares authorized, respectively; 5,429,384 and 3,111,691 shares issued and outstanding, respectively	5,429	3,112
Additional paid-in capital	22,880,390	22,371,230
Accumulated deficit	(23,714,735)	(23,426,640)
Total stockholders' deficiency	(828,916)	(1,052,298)
Total liabilities and stockholders' deficiency	$ 52,327	$ 73,868

XML

Stockholders' Equity (Details Textual)	9 Months Ended
	Jul. 31, 2013 Minimum [Member]	Jul. 31, 2013 Maximum [Member]	Jul. 31, 2013 2002 Equity Incentive Plan [Member]	Jul. 05, 2002 2002 Equity Incentive Plan [Member]	May 31, 2007 2007 Equity Incentive Plan [Member]	Jul. 31, 2013 2007 Equity Incentive Plan [Member] Minimum [Member]	Jul. 31, 2013 2007 Equity Incentive Plan [Member] Maximum [Member]
Stockholders' Equity (Textual)
Aggregate number of shares of common stock which could have been awarded				200,000	300,000	205,568	94,432
Stock options/ warrants outstanding, number of common shares available under outstanding stock options			147,000
Vesting period of options and warrants	5 years	10 years

XML

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012
Stock-Based Compensation (Textual)
Employee share-based compensation expense included in general and administrative expenses		$ 0		$ 3,716
Non employee share-based compensation expense included in general and administrative expenses	$ 0		$ 4,725

XML

Stock-Based Compensation

9 Months Ended

Jul. 31, 2013

Stock-Based Compensation [Abstract]

Stock-Based Compensation

7. Stock-Based Compensation

The Company accounts for stock-based payments to employees in accordance with Accounting Standards Codification 718, “Stock Compensation” (“ASC” 718”).  During the three and nine months ended July 31, 2013, the Company did not record any employee stock-based compensation expense.  During the three and nine months ended July 31, 2012, the Company recorded employee stock-based compensation expense of $0 and $3,716, respectively, which amounts were included in general and administrative expense.

The Company accounts for stock-based payments to non-employees in accordance with ASC 718 and Topic 505-50, “Equity-Based Payments to Non-Employees.”   During the three and nine months ended July 31, 2013, the Company recorded non-employee stock-based compensation expense of $0 and $4,725, respectively, which amounts were included in general and administrative expense.  During the three and nine months ended July 31, 2012, the Company did not record any non-employee stock-based compensation expense.

XML

Stockholders' Equity (Tables)

9 Months Ended

Jul. 31, 2013

Stock Option [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Summary of stock option/warrant transactions for employees and directors under the Equity Incentive Plans

	Stock Option  Shares			Weighted Average  Exercise Price Per Common Share		Aggregate  Intrinsic Value
Outstanding at October 31, 2012		249,532		$	1.57	$	700
Granted during the period		--			--
Exercised during the period		--			--
Expired during the period		(8,100	)	$	1.40
Outstanding at July 31, 2013		241,432		$	1.57	$	--
Exercisable at July 31, 2013		241,432		$	1.57	$	--
Exercisable at October 31, 2012		249,532		$	1.57	$	700

Schedule of outstanding and exercisable options and warrants

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number ofShares Available for Purchase Under Outstanding Stock Options		Weighted  Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.20		3,500	$	0.20		1.4		3,500	$	0.20		1.4
$	0.80		33,500	$	0.80		1.1		33,500	$	0.80		1.1
$	1.40		94,432	$	1.40		4.6		94,432	$	1.40		4.6
$	2.00		110,000	$	2.00		3.5		110,000	$	2.00		3.5
			241,432	$	1.57		3.5		241,432	$	1.57		3.5

Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Summary of stock option/warrant transactions for employees and directors under the Equity Incentive Plans

	Warrant Shares			Weighted Average  Exercise Price Per Common Share			Aggregate Intrinsic Value
Outstanding at October 31, 2012		93,000			$	1.19		$	--
Issued during the period		--				--
Exercised during the period		--				--
Expired during the period		(61,000	)		$	1.29
Outstanding at July 31, 2013		32,000			$	1.00		$	--
Exercisable at July 31, 2013		32,000			$	1.00		$	--
Exercisable at October 31, 2012		93,000			$	1.19		$	--

Schedule of outstanding and exercisable options and warrants

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average  Exercise Price Per Common  Share		Weighted Average Remaining Contractual  Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common  Share		Weighted Average Remaining Contractual Life (Years)
$	0.40		20,000	$	0.40		0.8		20,000	$	0.40		0.8
$	2.00		12,000	$	2.00		0.3		12,000	$	2.00		0.3
			32,000	$	1.00		0.6		32,000	$	1.00		0.6

XML

Convertible Debentures

9 Months Ended

Jul. 31, 2013

Notes Payable and Convertible Debentures [Abstract]

Convertible Debentures

6. Convertible Debentures

February 2007 Convertible Debentures

On February 8, 2007, the Company closed on a private placement of 8% convertible debentures dated February 1, 2007 (the “February 2007 Debentures”).  The gross proceeds received in connection with this private placement were $250,000.  The February 2007 Debentures originally had a three year term, maturing on January 31, 2010.  In January 2010, the holders agreed to a new maturity date of January 31, 2012, extending the term of the February 2007 Debentures for an additional two year period.

On January 11, 2012, the Company issued 50,000 shares of common stock at $1.00 per share as full payment of $50,000 of outstanding principal on certain February 2007 Debentures and 5,237 shares of common stock at per share prices ranging between $0.70 and $0.80 as full payment of $3,729 of accrued and unpaid interest related to those February 2007 Debentures.  Due to the reduction in the conversion price, the Company recorded a loss on conversion of these February 2007 Debentures of $21,750.

Effective January 31, 2012, certain holders of the February 2007 Debentures with an aggregate outstanding principal amount of $175,000, agreed to amend such February 2007 Debentures by extending the maturity date to January 31, 2014.  In addition, effective January 31, 2012, a holder of a February 2007 Debenture with an outstanding principal amount of $25,000 agreed to amend his February 2007 Debenture by extending the maturity date to July 31, 2012.  The Company has not made payment on this February 2007 Debenture and, as a result, such obligation can be placed in default by the holder.

For the three and nine months ended July 31, 2013, the Company recorded a total of $4,033 and $11,867, respectively, of interest expense related to the February 2007 Debentures.  For the three and nine months ended July 31, 2012, the Company recorded a total of $4,033 and $12,764, respectively, of interest expense related to the February 2007 Debentures.  As of July 31, 2013, $7,935 of interest due on the February 2007 Debentures was accrued and is included as a component of accrued expense.  As of July 31, 2013, the Company recorded the $200,000 of outstanding principal due on the February 2007 Debentures as a component of current convertible debentures.

May 2011 Convertible Debenture

On May 20, 2011, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “May 2011 Debenture”).  The May 2011 Debenture has a three year term maturing on May 20, 2014 and bears interest at a rate of 8% per annum.  For the three and nine months ended July 31, 2013, the Company recorded a total of $2,017 and $5,985, respectively, of interest expense related to the May 2011 Debenture.  For the three and nine months ended July 31, 2012, the Company recorded a total of $2,017 and $6,006, respectively, of interest expense related to the May 2011 Debenture.  As of July 31, 2013, $9,603 of interest due on the May 2011 Debenture was accrued and is included as a component of accrued expenses.  As of July 31, 2013, the Company recorded the $100,000 of outstanding principal due on the May 2011 Debenture as a component of current convertible debentures.

August 2012 Convertible Debenture

On August 15, 2012, the Company issued an 8% convertible debenture in the amount of $100,000 to an institutional investor (the “August 2012 Debenture”).  The August 2012 Debenture has a three year term maturing on August 15, 2015 and bears interest at a rate of 8% per annum.  For the three and nine months ended July 31, 2013, the Company recorded a total of $2,017 and $6,051, respectively, of interest expense related to the August 2012 Debenture.  As of July 31, 2013, $7,783 of interest due on the August 2012 Debenture was accrued and is included as a component of accrued expenses.  As of July 31, 2013, the Company recorded the $100,000 of outstanding principal due on the August 2012 Debenture as a component of non-current convertible debenture.

XML

Basis of Presentation

9 Months Ended

Jul. 31, 2013

Basis Of Presentation [Abstract]

Basis of Presentation

1. Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant recurring operating losses and negative cash flows from operations.  The Company had a working capital deficiency of $623,916 and an accumulated deficit of $23,714,735 as of July 31, 2013.  The Company also has no lending relationships with commercial banks and is dependent on the completion of a financing involving the private placement of its securities in order to continue operations.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company continues to seek equity and/or debt investors and from time to time engages placement agents to assist the Company in this initiative.  The Company has reduced operating expenses and, effective November 1, 2011, each of the Company’s officers agreed to waive the annual base salary due to them and each of the Company’s directors agreed to waive the annual retainer and meeting fees due to them until the Company is able to raise sufficient capital that would provide the Company with the ability to pay cash compensation to its officers and directors.

On January 23, 2013, the Company issued shares of its common stock as settlement of $225,627 of accrued compensation due through October 31, 2011 to its officers and other related costs, $17,000 of fees due through October 31, 2011 to its current independent directors and a former independent director and $95,000 due for office rent through January 31, 2013 ($80,000 accrued as of October 31, 2012).  The Company has also deferred certain other vendor payments until the Company secures sufficient additional financing.

While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts.  If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company.  Any additional equity financing may result in substantial dilution to our stockholders.

XML

Amended and Restated SCMS License Agreement (Details) (USD $)	9 Months Ended
	Jul. 31, 2013	Oct. 31, 2012	Jun. 03, 2011
Amended and Restated SCMS License Agreement (Textual)
Term of amended and restated license agreement, Description	Later of (a) the expiration date of the last to expire patent right related to the SCMS, which is currently May 1, 2027, or (b) 17 years from the sale of the first licensed product on a country by country basis.
Cash payment for licensing agreement to Hickey			$ 30,000
Cash payment due to Hickey on July 31, 2012 under the license agreement	105,000
Description of restructuring of cash payment due to Hickey under license agreement	(a) $50,000 is due to Hickey on or before a date that is thirty (30) days after the closing of any single financing by the Company of at least $3,000,000 or any series of financings by the Company within a six (6) month period totaling at least $3,000,000; and (b) $55,000 is due to Hickey on or before the date that is thirty (30) days after the first commercial sale of a product utilizing the licensed technology.
Notes payable due to Hickey	105,000	105,000
Amount of shares agreed to issue to licensor on date files for approval to market and sell a product utilizing the licensed technology	130,000
Amount of shares agreed to issue to licensor on date of receives approval to market and sell a product utilizing the licensed technology	160,000
Percentage of annual net sales payable to licensor as royalty under agreement	5.00%
Minimum royalty payment for first full year of sales of the SCMS in the United States and for two years thereafter	100,000
Minimum royalty payment for first full year of sales of the SCMS outside the United States and for two years thereafter	$ 100,000
Percentage of sublicensing revenue require to pay licensor under the Amended and Restated License Agreement	25.00%
Notice period incase of default in perform any covenant of the Amended and Restated License Agreement	90 days

XML

Stockholders' Equity

9 Months Ended

Jul. 31, 2013

Stockholders' Equity [Abstract]

Stockholders' Equity

9. Stockholders’ Equity

Stock Option Plans

The Company currently has two stock option plans in place:  the 2002 Equity Incentive Plan and the 2007 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).  The 2002 Equity Incentive Plan was approved by the stockholders on July 5, 2002.  The aggregate number of shares of common stock which could have been awarded under the 2002 Equity Incentive Plan was 200,000.  As of July 31, 2013, options to purchase 147,000 shares of the Company’s common stock were outstanding under the 2002 Equity Incentive Plan.  As a result of the adoption of the Company’s 2007 Equity Incentive Plan, no further awards are permitted under the 2002 Equity Incentive Plan.

On May 31, 2007, the stockholders approved the Company’s 2007 Equity Incentive Plan.  The 2007 Equity Incentive Plan was placed into effect in order to encourage and enable employees and directors of the Company to acquire or increase their holdings of the Company’s common stock and to promote these individuals’ interests in the Company thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company.  The 2007 Equity Incentive Plan provides for awards in the form of restricted shares, incentive stock options, non-qualified stock options and stock appreciation rights.  The aggregate number of shares of common stock which may be awarded under the 2007 Equity Incentive Plan is 300,000, subject to adjustment as provided in the 2007 Equity Incentive Plan.  As of July 31, 2013, options to purchase 94,432 shares of the Company’s common stock were outstanding under the 2007 Equity Incentive Plan and up to 205,568 shares of the Company’s common stock remain available for awards under the 2007 Equity Incentive Plan.

Stock option awards under the Equity Incentive Plans were granted at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company's common stock on the date of grant.  Stock options granted and outstanding include only non-qualified stock options and vest over a period of up to five years and have a maximum term of ten years from the date of grant.

A summary of stock option transactions for employees and directors under the Equity Incentive Plans during the nine months ended July 31, 2013 is as follows:

	Stock Option  Shares			Weighted Average  Exercise Price Per Common Share		Aggregate  Intrinsic Value
Outstanding at October 31, 2012		249,532		$	1.57	$	700
Granted during the period		--			--
Exercised during the period		--			--
Expired during the period		(8,100	)	$	1.40
Outstanding at July 31, 2013		241,432		$	1.57	$	--
Exercisable at July 31, 2013		241,432		$	1.57	$	--
Exercisable at October 31, 2012		249,532		$	1.57	$	700

Information with respect to stock options outstanding and stock options exercisable as of July 31, 2013 that were granted to employees is as follows:

		Stock Options Outstanding						Stock Options Exercisable
Exercise Price		Number of Shares Available Under Outstanding Stock Options		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)		Number ofShares Available for Purchase Under Outstanding Stock Options		Weighted  Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
$	0.20		3,500	$	0.20		1.4		3,500	$	0.20		1.4
$	0.80		33,500	$	0.80		1.1		33,500	$	0.80		1.1
$	1.40		94,432	$	1.40		4.6		94,432	$	1.40		4.6
$	2.00		110,000	$	2.00		3.5		110,000	$	2.00		3.5
			241,432	$	1.57		3.5		241,432	$	1.57		3.5

Warrants to Purchase Common Stock

A summary of warrant transactions during the nine months ended July 31, 2013 is as follows:

	Warrant Shares			Weighted Average  Exercise Price Per Common Share		Aggregate Intrinsic Value
Outstanding at October 31, 2012		93,000		$	1.19	$	--
Issued during the period		--			--
Exercised during the period		--			--
Expired during the period		(61,000	)	$	1.29
Outstanding at July 31, 2013		32,000		$	1.00	$	--
Exercisable at July 31, 2013		32,000		$	1.00	$	--
Exercisable at October 31, 2012		93,000		$	1.19	$	--

Information with respect to warrants outstanding and warrants exercisable at July 31, 2013 is as follows:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number of Shares Available Under Outstanding Warrants		Weighted Average  Exercise Price Per Common  Share		Weighted Average Remaining Contractual  Life (Years)		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Exercise Price Per Common  Share		Weighted Average Remaining Contractual Life (Years)
$	0.40		20,000	$	0.40		0.8		20,000	$	0.40		0.8
$	2.00		12,000	$	2.00		0.3		12,000	$	2.00		0.3
			32,000	$	1.00		0.6		32,000	$	1.00		0.6

XML

Convertible Debentures (Details) (USD $)		0 Months Ended			1 Months Ended	3 Months Ended		9 Months Ended				1 Months Ended	3 Months Ended		9 Months Ended		0 Months Ended	3 Months Ended	9 Months Ended
	Mar. 20, 2013	Jan. 11, 2012 February 2007 Convertible Debentures [Member]	Jan. 31, 2010 February 2007 Convertible Debentures [Member]	Feb. 08, 2007 February 2007 Convertible Debentures [Member]	Jan. 31, 2012 February 2007 Convertible Debentures [Member]	Jul. 31, 2013 February 2007 Convertible Debentures [Member]	Jul. 31, 2012 February 2007 Convertible Debentures [Member]	Jul. 31, 2013 February 2007 Convertible Debentures [Member]	Jul. 31, 2012 February 2007 Convertible Debentures [Member]	Jan. 11, 2012 February 2007 Convertible Debentures [Member] Maximum [Member]	Jan. 11, 2012 February 2007 Convertible Debentures [Member] Minimum [Member]	May 20, 2011 May 2011 Convertible Debenture [Member]	Jul. 31, 2013 May 2011 Convertible Debenture [Member]	Jul. 31, 2012 May 2011 Convertible Debenture [Member]	Jul. 31, 2013 May 2011 Convertible Debenture [Member]	Jul. 31, 2012 May 2011 Convertible Debenture [Member]	Aug. 15, 2012 August 2012 Convertible Debenture [Member]	Jul. 31, 2013 August 2012 Convertible Debenture [Member]	Jul. 31, 2013 August 2012 Convertible Debenture [Member]
Convertible Debenture (Textual)
Interest rate on convertible debentures	9.30%			8.00%								8.00%					8.00%
Convertible debt				$ 250,000								$ 100,000					$ 100,000
Shares issued for repayment of convertible debentures		50,000
Convertible debt conversion price		$ 1.00
Principal amount of debentures		50,000
Shares issued for payment of accrued interest		5,237
Conversion price shares converted for full payment accrued and unpaid interest					$ 1.00					$ 0.80	$ 0.70
Accrued and unpaid interest of convertible debt converted into shares		3,729
Loss on conversion of convertible debt		21,750
Principal amount of loan from IPFS	20,220				175,000
Debt Instrument Maturity Term												Debenture has a three year term maturing					Debenture has a three year term maturing
Original term of debt maturity				3 years
Extension period of debt			2 years
Original maturity date of debentures				Jan. 31, 2010
Second amended maturity date of debentures			Jan. 31, 2012
Principal amount of debentures with extended maturity					25,000
Debt instrument, maturity date					Jan. 31, 2014							May 20, 2014					Aug. 15, 2015
Accrued interest						7,935		7,935					9,603		9,603			7,783	7,783
Interest expense						4,033	4,033	11,867	12,764				2,017	2,017	5,985	6,006		2,017	6,051
Principal outstanding of current convertible debentures						200,000		200,000					100,000		100,000
Principal outstanding of non current convertible debentures																		$ 100,000	$ 100,000

XML

Related Party Transactions (Details) (Mr. LaVance and Mr. Gifford [Member], USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2013 sqft	Jul. 31, 2012	Jul. 31, 2013 sqft	Jul. 31, 2012
Mr. LaVance and Mr. Gifford [Member]
Related Party Transactions (Textual)
Area of office space	2,000		2,000
Notice period to terminate sublease agreement			60 days
Monthly rental fee			$ 5,000
Sublease agreement expenses	24,905	17,730	59,662	54,297
Rent expenses included in accounts payable - related party	30,000		30,000
Other expenses included in accounts payable - related party	$ 27,389		$ 27,389

XML

Document and Entity Information	9 Months Ended
	Jul. 31, 2013	Sep. 13, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	SCIVANTA MEDICAL CORP
Entity Central Index Key	0001093285
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Document Type	10-Q
Document Period End Date	Jul. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,429,384

XML

Note Payable (Details) (USD $)	0 Months Ended	3 Months Ended	9 Months Ended
	Mar. 20, 2013 Installments	Jul. 31, 2013	Jul. 31, 2013
Notes Payable (Textual)
Principal amount of loan from IPFS	$ 20,220
Interest rate on loan from IPFS	9.30%
Monthly payment of Notes payable with IPFS	2,335
Notes payable - IPFS, date of first required payment	Apr. 13, 2013
Notes payable - IPFS, number of periodic payments	9
Interest expense related to financing agreement with IPFS		229	526
Notes payable - IPFS, outstanding		$ 11,407	$ 11,407